News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myriad Genetics, Inc. (MYGN)'s Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study


3/5/2013 11:26:52 AM

SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES